Table 1.
Ongoing clinical trials of KRASG12C-targeted inhibitors and related combination therapy clinical trials.
| Drug | Treatment Strategy | ClinicalTrials.gov registration | Disease setting | Study phase | Recruitment Status |
|---|---|---|---|---|---|
| AMG510 (Sotorasib) | Monotherapy | NCT03600883 | Advanced solid tumors with KRAS G12C mutations | I/II | Active, not recruiting |
| Monotherapy | NCT04667234 | Advanced/unresectable/metastatic NSCLC with KRASG12C mutation | / | Available | |
| Monotherapy | NCT04380753 | Advanced/Metastatic Solid Tumors with KRASG12C Mutations | I | Active, not recruiting | |
| Monotherapy | NCT04625647 | Advanced NSCLC with KRAS G12C mutations | II | Recruiting | |
| Monotherapy | NCT04933695 | Stage IV NSCLC with KRAS G12C mutations without prior treatment | II | Active, not recruiting | |
| Monotherapy | NCT05400577 | Stage IV NSCLC with KRAS G12C mutations without prior treatment | II | Recruiting | |
| Monotherapy | NCT05398094 | Stage III unresectable NSCLC with KRAS G12C mutations | II | Recruiting | |
| Monotherapy | NCT05273047 | Metastatic NSCLC with KRAS G12C mutations | / | Recruiting | |
| Monotherapy | NCT05451056 | NSCLC with KRAS G12C mutations | II | Not yet recruiting | |
| Monotherapy vs. Docetaxel | NCT04303780 | Advanced NSCLC with KRAS G12C mutations | Ⅲ | Active, not recruiting | |
| Combined with Tarloxotinib | NCT05313009 | NSCLC with KRAS G12C mutations | I/II | Recruiting | |
| Combined with BBP-398 | NCT05480865 | Advanced solid tumors with KRAS G12C mutations | I | Recruiting | |
| Combined with VS-6766 | NCT05074810 | NSCLC with KRAS G12C mutations | I/II | Recruiting | |
| Combined with targeted therapy, chemotherapy, or immunotherapy | NCT04185883 | Advanced Solid tumors with KRAS G12C mutations | I/II | Recruiting | |
| Combined with Panitumumab vs. Trifluridine and Tipiracil,or Regorafenib | NCT05198934 | CRC with KRAS G12C mutations | Ⅲ | Active, not recruiting | |
| Combined with MVASI | NCT05180422 | Advanced, unresectable or metastatic KRASG12C mutant NSCLC With asymptomatic brain metastasis | I/II | Recruiting | |
| Combined with Panitumumab | NCT05638295 | Advanced/Metastatic Solid Tumors With KRASG12C Mutation | II | Not yet recruiting | |
| Combined with RMC-4630 | NCT05054725 | NSCLC with KRAS G12C mutations | II | Recruiting | |
| Combined with cisplatin or carboplatin and pemetrexed | NCT05118854 | Stage IIA-IIIB resectable non-squamous NSCLC with KRAS G12C mutations | II | Recruiting | |
| MRTX849 (Adagrasib) | Monotherapy | NCT05162443 | Advanced solid tumors with KRAS G12C mutations | / | Available |
| Monotherapy | NCT05263986 | Advanced/Metastatic Solid Tumors With KRASG12C Mutations | I | Active, not recruiting | |
| Monotherapy | NCT05634525 | Metastatic pancreatic cancer with KRAS mutations | I | Not yet recruiting | |
| Monotherapy | NCT05673187 | Stage IV NSCLC with KRAS G12C mutations | II | Not yet recruiting | |
| Monotherapy or combined with Nivolumab | NCT05472623 | Resectable NSCLC with KRAS G12C mutations | II | Not yet recruiting | |
| Monotherapy or combined with Cetuximab or Pembrolizumab or Afatinib | NCT03785249 | Advanced solid tumors with KRAS G12C mutations | I/II | Recruiting | |
| Monotherapy or combined with Pembrolizumab | NCT04613596 | Advanced or metastatic NSCLC with KRAS G12C mutations | II/Ⅲ | Recruiting | |
| Monotherapy vs. Docetaxel | NCT04685135 | Advanced or metastatic NSCLC with KRAS G12C mutations | Ⅲ | Recruiting | |
| Combined with Cetuximab vs. Chemotherapy | NCT04793958 | Advanced CRC with KRAS G12C mutations | Ⅲ | Recruiting | |
| Combined with BI 1701963 | NCT04975256 | Advanced solid tumors with KRAS G12C mutations | I | Completed | |
| Combined with Palbociclib | NCT05178888 | Advanced solid tumors with KRAS G12C mutations | I | Active, not recruiting | |
| Combined with TNO155 | NCT04330664 | Advanced solid tumors with KRAS G12C mutations | I/II | Active, not recruiting | |
| Combined with SAR442720 | NCT04418661 | NSCLC with KRAS G12C mutations | / | Active, not recruiting | |
| Combined with Pembrolizumab | NCT05609578 | Advanced NSCLC with KRAS G12C mutations | II | Recruiting | |
| Combined with Cetuximab and Irinotecan | NCT05722327 | CRC with KRAS G12C mutations | I | Not yet recruiting | |
| Combined with VS-6766 | NCT05375994 | NSCLC with KRAS G12C mutations | I/II | Recruiting | |
| JAB-21822 | Monotherapy | NCT05009329 | Advanced solid tumors with KRAS G12C mutations | I/II | Recruiting |
| Monotherapy | NCT05276726 | Advanced or metastatic NSCLC with KRAS G12C mutations | I/II | Recruiting | |
| Monotherapy or combined with Cetuximab | NCT05002270 | Advanced solid tumors with KRAS G12C mutations | I/II | Recruiting | |
| Combined with JAB-3312 | NCT05288205 | Advanced solid tumors with KRAS G12C mutations | I/II | Recruiting | |
| Combined with Cetuximab | NCT05194995 | Advanced solid tumors with KRAS G12C mutations | I/II | Recruiting | |
| JDQ443 | Monotherapy | NCT05329623 | Small Cell Lung Carcinoma | I | Suspended |
| Monotherapy | NCT05445843 | Advanced or metastatic NSCLC with KRAS G12C mutations | II | Recruiting | |
| Monotherapy | NCT05132075 | Advanced NSCLC with KRAS G12C mutations | Ⅲ | Recruiting | |
| Monotherapy or combined with TNO155 or tislelizumab or TNO155 + tislelizumab | NCT04699188 | Advanced solid tumors with KRAS G12C mutations | I/II | Recruiting | |
| Combined with Trametinib or Ribociclib or cetuximab | NCT05358249 | Advanced solid tumors with KRAS G12C mutations | I/II | Recruiting | |
| GDC-6036 | Monotherapy vs. Docetaxel | NCT03178552 | Advanced/unresectable/metastatic NSCLC | II/Ⅲ | Recruiting |
| Monotherapy or combined with chemotherapy, immunotherapy, etc. | NCT04449874 | Advanced or metastatic NSCLC with KRAS G12C mutations | I | Recruiting | |
| Combined with Pembrolizumab | NCT05789082 | Advanced or metastatic NSCLC with KRAS G12C mutations | I/II | Not yet recruiting | |
| Combined with Cetuximab | NCT04929223 | Metastatic CRC | II/Ⅲ | Recruiting | |
| D-1553 | Monotherapy | NCT05383898 | Advanced or metastatic NSCLC with KRAS G12C mutations | I/II | Recruiting |
| Monotherapy or combined with other therapies | NCT04585035 | Advanced or metastatic NSCLC with KRAS G12C mutations | I/II | Recruiting | |
| Combined with immunotherapy or targeted therapy | NCT05492045 | Advanced or metastatic NSCLC with KRAS G12C mutations | I/II | Not yet recruiting | |
| Combined with IN10018 | NCT05379946 | Advanced or metastatic NSCLC with KRAS G13C mutations | I/II | Not yet recruiting | |
| D3S-001 | Monotherapy | NCT05410145 | Advanced solid tumors with KRAS G12C mutations | I | Recruiting |
| GFH925 | Monotherapy | NCT05005234 | Advanced solid tumors with KRAS G12C mutations | I/II | Recruiting |
| YL-15293 | Monotherapy | NCT05119933 | Advanced solid tumors with KRAS G12C mutations | I/II | Recruiting |
| JNJ-74699157 | Monotherapy | NCT04006301 | Advanced solid tumors with KRAS G12C mutations | I | Completed |
| RMC-6291 | Monotherapy | NCT05462717 | Advanced solid tumors with KRAS G12C mutations | I | Recruiting |
| HS-10370 | Monotherapy | NCT05367778 | Advanced solid tumors with KRAS G13C mutations | I/II | Not yet recruiting |
| MK-1084 | Monotherapy or combined with Pembrolizumab | NCT05067283 | Advanced solid tumors with KRAS G14C mutations | I | Recruiting |
| LY3537982 | Monotherapy or combined with targeted therapy, immunotherapy, etc. | NCT04956640 | Advanced solid tumors with KRAS G12C mutations | I | Recruiting |